Your shopping cart is currently empty

MKC8866 is a selective IRE1 RNase inhibitor (IC50: 0.29 μM in human vitro). MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibit prostate cancer (PCa) tumor growth.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $80 | In Stock | In Stock | |
| 2 mg | $117 | In Stock | In Stock | |
| 5 mg | $197 | In Stock | In Stock | |
| 10 mg | $277 | In Stock | In Stock | |
| 25 mg | $469 | In Stock | In Stock | |
| 50 mg | $619 | In Stock | In Stock | |
| 100 mg | $845 | In Stock | In Stock | |
| 200 mg | $1,130 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $213 | In Stock | In Stock |
| Description | MKC8866 is a selective IRE1 RNase inhibitor (IC50: 0.29 μM in human vitro). MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibit prostate cancer (PCa) tumor growth. |
| Targets&IC50 | IRE1 Rnase:0.29 μM |
| In vitro | MKC8866 strongly suppresses DTT-induced X-box-binding protein 1-spliced (XBP1s) expression (EC50: 0.52?μM) and unstressed RPMI 8226 cells (IC50: 0.14?μM). MKC8866 (0.2-10 μM; 3 days) inhibits the viability of all four cell lines in a dose-dependent manner under normal conditions, with the most robust effect in LNCaP cells, and MKC8866 (20 μM; 72?hours) is sufficient to completely block NSC 125973-induced expression of XBP1s [1]. MKC8866 (20?μM; 6 days) reduces the proliferation of all breast cancer cell lines and MKC8866 (20 μM; 48 hours) decreases the number of cells entering the S phase [2]. |
| In vivo | MKC8866 (oral; 300 mg/kg; for 28 days) reduces tumor regrowth following NSC 125973 withdrawal [1]. |
| Molecular Weight | 361.35 |
| Formula | C18H19NO7 |
| Cas No. | 1338934-59-0 |
| Smiles | COc1cc2c(C)c(CC(=O)N3CCOCC3)c(=O)oc2c(C=O)c1O |
| Relative Density. | 1.373 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 4.8 mg/mL (13.28 mM), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.